Cherington Charles10% owner
4
Filed Feb 17, 2026Period of report Feb 10, 20260001104659-26-016680
| Transaction | Security | Shares | Price | ValueValue (shares × price) | Held after | Ownership |
|---|---|---|---|---|---|---|
PurchaseFeb 10, 2026 | Common StockF1F2 | 4,000,000 | $0.50 | Not counted | 6,779,440 | Direct |
Filing footnotes · 3
- F1These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026.
- F2The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50.
- F3The warrants will expire on the earlier of (i) February 10, 2031 or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.